Advanced Solid Tumors (various)
PYXSPyxis OncologyCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Micvotabart pelidotin (MICVO, formerly PYX-201) + KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors (various). The expected timing is based on the latest available company guidance and may change.
PYX-201-102 trial. Collab w/ MSD. 2/4/25- Actively recruiting. 11/3/25- Additional prelim clinical data from 1L/2L+ R/M HNSCC patients in Q4 2025. 11/03/25:- Q4 25 addl Ph1/2 data planned 12/18/25:- Updated Ph1/2 MICVO+pembro data in R/M HNSCC; broader tumor data expected H2 2026. 03/23/26:- 2H26 Ph1/2 MICVO+KEYTRUDA data in 1L/2L+ R/M HNSCC remains on track. 05/14/26:- 2H26 MICVO+KEYTRUDA Ph1/2 update remains on track, now focused on 1L R/M HNSCC. 08/13/26:- Updated Phase 1/2 MICVO plus pembrolizumab data in 1L R/M HNSCC will be reported in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.